Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Study of Levalbuterol, Racemic Albuterol and Placebo in Subjects Twelve Years of Age and Older With Asthma

This study has been completed.
Information provided by (Responsible Party):
Sunovion Identifier:
First received: December 9, 2003
Last updated: February 21, 2012
Last verified: February 2012
The primary purpose of this study was to investigate the efficacy of levalbuterol compared to a placebo and compared to albuterol in the treatment and prevention of bronchoconstriction in adolescent and adult subjects with asthma, with all treatments administered 4 times a day (QID).

Condition Intervention Phase
Drug: levalbuterol tartrate MDI
Drug: racemic albuterol MDI
Drug: Placebo
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double Blind (Participant, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: An Efficacy and Safety Study of Levalbuterol, Racemic Albuterol and Placebo in Subjects Twelve Years of Age and Older With Asthma

Resource links provided by NLM:

Further study details as provided by Sunovion:

Primary Outcome Measures:
  • percent change in FEV1 from visit predose averaged over the 8-week double-blind period [ Time Frame: Weeks 0, 4, 8 ]

Secondary Outcome Measures:
  • area under the FEV1 percent change curve from visit pre-dose and from study baseline curves averaged over the double-blind period [ Time Frame: Weeks 0, 4, 8 ]
  • peak percent change in FEV1 from study baseline [ Time Frame: Weeks 0, 4, 8 ]
  • peak change in FEV1 from visit predose [ Time Frame: Weeks 0, 4, 8 ]
  • peak percent of predicted FEV1 [ Time Frame: Weeks 0, 4, 8 ]
  • area under the FEV1 curve (AUC) [ Time Frame: Weeks 0, 4, 8 ]
  • peak change and peak percent change in FEF25-75% from visit predose [ Time Frame: Weeks 0, 4, 8 ]
  • peak change and peak percent change in FVC from visit predose [ Time Frame: Weeks 0, 4, 8 ]

Enrollment: 445
Study Start Date: May 2002
Study Completion Date: January 2003
Primary Completion Date: January 2003 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1
levalbuterol MDI 90 mcg QID
Drug: levalbuterol tartrate MDI
levalbuterol 90 mcg QID
Other Name: Xopenex MDI
Active Comparator: 2
racemic albuterol MDI 180 mcg QID
Drug: racemic albuterol MDI
racemic albuterol 180 mcg QID
Placebo Comparator: 3
Placebo MDI QID
Drug: Placebo
Placebo MDI QID

Detailed Description:
This was a Phase III, multicenter, randomized, double-blind, placebo- and active-controlled, parallel-group study of up to 9 weeks in duration. Seven days of QID single-blind placebo administration (via MDI) was followed by 56 days of QID double-blind active treatment. Following the run-in period, each subject was randomized to one of the following three treatments: levalbuterol HFA MDI 90 mcg (2 actuations of 45 mcg), racemic albuterol HFA MDI 180 mcg (2 actuations of 90 mcg), or placebo (2 actuations). Subjects were randomized in a 2:1:1 ratio of levalbuterol to racemic albuterol to placebo. In order to maintain blinding of the device, a placebo dose was administered with each treatment. This study was previously posted by Sepracor Inc. In October 2009, Sepracor Inc. was acquired by Dainippon Sumitomo Pharma., and in October 2010, Sepracor Inc's name was changed to Sunovion Pharmaceuticals Inc.

Ages Eligible for Study:   12 Years and older   (Child, Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria

  • Willing and able to comply with the study procedures and visit schedules
  • Male or female, at least 12 years of age
  • Female subjects 12-60 years of age must have a negative serum pregnancy test at study start.
  • Women of child bearing potential must be using an acceptable method of birth control
  • Have a documented diagnosis of asthma for a minimum of 6 months prior to study start
  • Must have stable baseline asthma and have been using a B-adrenergic agonist, and/or anti-asthma anti-inflammatory medication, and/or OTC asthma medication for at least 6 months prior to study start
  • Must be in good health with the exception of their reversible airways disease and not suffering from any chronic condition that might affect their respiratory function
  • Must have a chest X-ray that is not diagnostic of pneumonia, atelectasis, pulmonary fibrotic disease, pneumothorax, chronic obstructive pulmonary disease, etc.
  • Must be able to complete the diary cards and medical event calendars reliably on a daily basis, understand dosing instructions, and demonstrate how to use the MiniWright PEF meter.

Exclusion Criteria

  • Female subject who is pregnant or lactating
  • Have participated in an investigational drug study within 30 days prior to study start, or who is currently participating in another clinical trial
  • Subject whose schedule prevents him or her from taking the first daily dose of study medication and/or starting study visits before 9 AM
  • Subject who has travel commitments during the study that would interfere with trial measurements or compliance
  • Have a history of hospitalization for asthma within 45 days prior to study start, or who is scheduled for in-patient hospitalization, including elective surgery
  • Have a known sensitivity to levalbuterol or racemic albuterol, or any excipients in any of these formulations
  • Subject using any prescription drug with which albuterol sulfate administration is contraindicated
  • Subject with currently diagnosed life-threatening asthma
  • History of cancer (exception: basal cell carcinoma in remission).
  • Subject with hyperthyroidism, diabetes, hypertension, cardiac diseases or seizure disorders that currently are not well controlled by medication
  • History of substance abuse or drug abuse within 12 months preceding study start
  • Subject with greater than 10 pack year history of cigarette smoking or use of any tobacco products within 6 months of study start
  • Documented history of bronchopulmonary aspergillosis or any form of allergic alveolitis
  • Have suffered from a clinically significant upper or lower respiratory tract infection in the 2 weeks prior to study start
  • Subject who is a staff member or relative of a staff member
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00073827

  Show 63 Study Locations
Sponsors and Collaborators
  More Information

Responsible Party: Sunovion Identifier: NCT00073827     History of Changes
Other Study ID Numbers: 051-353
Study First Received: December 9, 2003
Last Updated: February 21, 2012

Keywords provided by Sunovion:

Additional relevant MeSH terms:
Bronchial Diseases
Respiratory Tract Diseases
Lung Diseases, Obstructive
Lung Diseases
Respiratory Hypersensitivity
Hypersensitivity, Immediate
Immune System Diseases
Bronchodilator Agents
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Anti-Asthmatic Agents
Respiratory System Agents
Tocolytic Agents
Reproductive Control Agents
Adrenergic beta-2 Receptor Agonists
Adrenergic beta-Agonists
Adrenergic Agonists
Adrenergic Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action processed this record on April 27, 2017